J&J is off to a strong start in 2026 — here's how our newest stock can build on it

Johnson & Johnson delivered a beat-and-raise quarter, with Q1 revenue up 9.9% to $24.06 billion versus $23.63 billion expected and adjusted EPS of $2.70 versus $2.66. Growth was led by Darzalex sales of $3.96 billion (+22.5%) and Tremfya sales of $1.61 billion (+68%), while the newly approved psoriasis pill Icotyde adds another potential growth driver. J&J raised full-year guidance for sales to $100.3 billion-$101.3 billion and adjusted EPS to $11.45-$11.65, and shares rose about 1%.

Analysis

JNJ’s real signal is not the headline beat; it is that the company is now compounding through portfolio mix rather than one-off cost actions. The market should start treating the stock less like a defensive pharma utility and more like a self-funding growth platform: as Stelara declines become less of an absolute drag over the next 2-3 quarters, the earnings mix can re-rate even if topline growth only stays mid-single digits. That matters because the valuation has already moved into a regime where investors are paying for visibility, so each incremental proof point on pipeline durability has an outsized effect on multiple expansion.

The biggest second-order winner is the “next layer” of autoimmune care, not just JNJ’s own drugs. Icotyde’s oral format creates a convenience wedge that can shift prescribing behavior away from injectable incumbents, which is a direct competitive problem for AbbVie’s psoriasis franchise and, more broadly, for any biologic whose adherence depends on office visits or self-injection tolerance. If oral uptake is faster than expected, it could also force payers to re-open formulary negotiations across the IL-23 class, creating a pricing overhang for rivals sooner than the street is modeling.

MedTech is the quieter catalyst: even if the segment is merely stable today, Ottava gives JNJ a credible option on a market where incumbency has historically been worth several turns of multiple premium. The key is not near-term revenue contribution but strategic leverage—successful FDA progression would let JNJ offset pharma concentration risk with a higher-duration device growth engine. Conversely, any delay would matter more to sentiment than earnings, because the stock’s current multiple already assumes the pipeline story is real and diversified.

The contrarian miss is that consensus is still anchoring too hard to the size of the company rather than the slope of the growth curve. A $100B+ revenue base does not need double-digit growth to keep the stock working; it needs sustained low-to-mid single-digit acceleration plus margin expansion, which is exactly the kind of setup that tends to rerate over 12-18 months. The main risk is that 2026 optimism gets pulled forward too aggressively, leaving the shares vulnerable to a post-earnings digestion period if follow-through on Icotyde prescriptions or Ottava milestones is slower than headline enthusiasm implies.

Key Decisions for Investors

• Stay long JNJ on a 6-12 month horizon; the risk/reward is favorable while Stelara headwinds are still fading and growth mix is improving. Add on any 3-5% pullback, with the thesis invalidated only if the next two quarters fail to show sequential acceleration in Innovative Medicine.
• Pair trade: long JNJ / short ABBV over the next 3-9 months. The market is likely underpricing oral Icotyde as a share-shifter in psoriasis/IBD while ABBV faces a more direct biosimilar and class-competition wall; target modest relative outperformance rather than absolute beta.
• Buy JNJ call spreads 6-12 months out to express the view that the multiple can expand one more turn as growth confidence improves. Favor structures that cap upside but minimize theta, since the catalyst path is gradual rather than binary.
• Use ISRG as a tactical hedge against Ottava enthusiasm: if JNJ’s robotic platform gains credibility, the market may re-rate the competing surgical monopoly lower on the margin. This is a low-conviction relative-value short only on FDA milestone headlines, not a structural short.
• Do not chase KVUE as a read-through; the consumer spin is largely irrelevant to the current debate. The better expression is within pharma/medtech where the portfolio mix and pipeline duration are changing the earnings quality over the next 12-24 months.